NCT06052449

Assessing Social Determinants of Health to Increase Cancer Screening

Completed NA Results posted Last updated 11 March 2026

What this trial tests

NA trial testing Social determinants of health screening assessment and referral process in Lung Cancer in 101 participants. Completed in 19 August 2025.

Timeline

30 September 2023

Primary endpoint
19 August 2025

19 August 2025

Quick facts

Lead sponsor	Hackensack Meridian Health
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	screening
Enrollment	101
Start date	30 September 2023
Primary completion	19 August 2025
Estimated completion	19 August 2025
Sites	1 location across United States

Drugs / interventions tested

• Social determinants of health screening assessment and referral process
• Current practice - Community-based lunch cancer screening (LungTalk)

Conditions studied

• Lung Cancer — all drugs for Lung Cancer →

Sponsor

Hackensack Meridian Health — full company profile →

Who can join

Adults 50 to 80, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Lung Cancer Screening Uptake Primary · 1 months post intervention

Number of participants in the two groups that get screened (have a computed tomography (CT or CAT) scan)

Group	Value	95% CI
Community-based Lung Cancer Screening (LungTalk)	1
Social Determinants of Health Screening (LungTalk + SDoH)	5

Health Literacy Secondary · Baseline

Health Literacy will be measured using the 3-item health literacy scale ranging from 0 (low health literacy level) to 12 (high health literacy level)

Group	Value	95% CI
Community-based Lung Cancer Screening (LungTalk)	11	7.75 – 12
Social Determinants of Health Screening (LungTalk + SDoH)	11	6 – 12

Health Literacy Secondary · 1 months post intervention

Health Literacy will be measured using the 3-item health literacy scale ranging from 0 (low health literacy level) to 12 (high health literacy level)

Group	Value	95% CI
Community-based Lung Cancer Screening (LungTalk)	10	8 – 12
Social Determinants of Health Screening (LungTalk + SDoH)	10	5 – 12

Medical Mistrust Secondary · Baseline

Medical Mistrust will be measured with 5 items ranging from 5 (low mistrust) to 25 (high mistrust)

Group	Value	95% CI
Community-based Lung Cancer Screening (LungTalk)	11	5 – 15
Social Determinants of Health Screening (LungTalk + SDoH)	11	5 – 13

Medical Mistrust Secondary · 1 months post intervention

Medical Mistrust will be measured with 5 items ranging from 5 (low mistrust) to 25 (high mistrust)

Group	Value	95% CI
Community-based Lung Cancer Screening (LungTalk)	10	5 – 11.25
Social Determinants of Health Screening (LungTalk + SDoH)	5	5 – 15.25

Perceived Smoking-Related Stigma Secondary · Baseline

Perceived Smoking-Related Stigma will be measured using the 5-item smoking-related stigma subscale of the Cataldo Lung Cancer Stigma Scale ranging from 5 (low perceived stigma) to 25 (high perceived stigma)

Group	Value	95% CI
Community-based Lung Cancer Screening (LungTalk)	20.5	17 – 24
Social Determinants of Health Screening (LungTalk + SDoH)	21	16 – 22

Perceived Smoking-Related Stigma Secondary · 1 months post intervention

Perceived Smoking-Related Stigma will be measured using the 5-item smoking-related stigma subscale of the Cataldo Lung Cancer Stigma Scale ranging from 5 (low perceived stigma) to 25 (high perceived stigma)

Group	Value	95% CI
Community-based Lung Cancer Screening (LungTalk)	21	18 – 22
Social Determinants of Health Screening (LungTalk + SDoH)	20	16 – 23.5

Lung Cancer Fatalism Secondary · Baseline

Lung Cancer Fatalism will be measured with 11 items ranging from 0 (no fatalism) to 11 (high fatalism)

Group	Value	95% CI
Community-based Lung Cancer Screening (LungTalk)	2	0 – 6
Social Determinants of Health Screening (LungTalk + SDoH)	2	0 – 6

Lung Cancer Fatalism Secondary · 1 months post intervention

Lung Cancer Fatalism will be measured with 11 items ranging from 0 (no fatalism) to 11 (high fatalism)

Group	Value	95% CI
Community-based Lung Cancer Screening (LungTalk)	1	0 – 5.25
Social Determinants of Health Screening (LungTalk + SDoH)	2	0 – 7.25

Knowledge of Lung Cancer and Lung Screening Secondary · Baseline

Knowledge of Lung Cancer and Lung Screening will be assessed with a 7-item multidimensional scale used in our preliminary studies adapted from literature specific to lung cancer. Several aspects will be assessed, including knowledge of lung cancer, risk, and screening. Range of scores is 0 (no knowledge) to 7 (high level of knowledge).

Group	Value	95% CI
Community-based Lung Cancer Screening (LungTalk)	4	3 – 5
Social Determinants of Health Screening (LungTalk + SDoH)	4	3 – 5

Knowledge of Lung Cancer and Lung Screening Secondary · 1 months post intervention

Knowledge of Lung Cancer and Lung Screening will be assessed with a 7-item multidimensional scale used in our preliminary studies adapted from literature specific to lung cancer. Several aspects will be assessed, including knowledge of lung cancer, risk, and screening. Range of scores is 0 (no knowledge) to 7 (high level of knowledge).

Group	Value	95% CI
Community-based Lung Cancer Screening (LungTalk)	5	2 – 7
Social Determinants of Health Screening (LungTalk + SDoH)	3	0 – 6

Perceived Barriers to Lung Cancer Screening Scale Secondary · Baseline

Perceived Barriers to Lung Cancer Screening Scale will be used ranging from 17 (low perceived barriers to lung screening) to 68 (high perceived barriers to lung screening).

Group	Value	95% CI
Community-based Lung Cancer Screening (LungTalk)	33.5	20 – 41
Social Determinants of Health Screening (LungTalk + SDoH)	35	23 – 40

Sponsor's own description

A multilevel lung screening intervention that pairs Social Determinants of Health (SDoH) screening and referral with a tailored health communication and decision support tool for lung screening has the potential to significantly impact lung screening uptake among at-risk individuals in the community, particularly among those who face barriers related to SDoH. In addition, findings will advance the understanding of effective strategies for improving lung screening and prevention efforts in non-traditional settings, with the ultimate goal of reducing the burden of lung cancer. As ways to support the realization of the public health benefit of lung cancer screening are considered, multiple strategies and venues to reach, and intervene, with screening-eligible is key.

The goal of this study is to compare the effectiveness of a community-based lung screening educational tool paired with a social determinants of health (SDoH) screening assessment and referral process compared to a community-based lung cancer screening (LCS) educational tool alone as part of community outreach activities to improve (a) LCS rates (primary outcome); (b) intention to screen; and (c) individual-level potential drivers of LCS (health literacy, mistrust, stigma, fatalism, knowledge, health beliefs). It is hypothesized that providing SDoH screening and referral will result in higher levels of LCS, forward movement of intention to screen, and improved individual-level drivers of LCS.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.